Biodesix Stock Today
| BDSX Stock | USD 1.44 0.01 0.70% |
Performance0 of 100
| Odds Of DistressOver 82
|
Biodesix is trading at 1.44 as of the 30th of November 2024; that is 0.70 percent increase since the beginning of the trading day. The stock's open price was 1.43. Biodesix has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Biodesix are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of September 2024 and ending today, the 30th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of October 2020 | Category Healthcare | Classification Health Care |
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado. Biodesix operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 145.47 M outstanding shares of which 388.86 K shares are currently shorted by private and institutional investors with about 1.13 trading days to cover. More on Biodesix
Moving against Biodesix Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Biodesix Stock Highlights
| CEO President | Scott Hutton | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBiodesix can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Biodesix's financial leverage. It provides some insight into what part of Biodesix's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Biodesix (BDSX) is traded on NASDAQ Exchange in USA. It is located in 919 West Dillon Road, Louisville, CO, United States, 80027 and employs 217 people. Biodesix is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 209.47 M. Biodesix conducts business under Biotechnology sector and is part of Health Care industry. The entity has 145.47 M outstanding shares of which 388.86 K shares are currently shorted by private and institutional investors with about 1.13 trading days to cover.
Biodesix currently holds about 15.18 M in cash with (22.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.36.
Check Biodesix Probability Of Bankruptcy
Ownership AllocationBiodesix holds a total of 145.47 Million outstanding shares. Biodesix retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Biodesix Ownership Details
Biodesix Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Lmr Partners Llp | 2024-06-30 | 1.6 M | |
| Essex Investment Management Company, Llc | 2024-09-30 | 971.2 K | |
| Wells Fargo & Co | 2024-06-30 | 931.2 K | |
| Geode Capital Management, Llc | 2024-09-30 | 804.6 K | |
| Perkins Capital Management Inc | 2024-09-30 | 724.8 K | |
| Amh Equity Ltd | 2024-09-30 | 696.1 K | |
| Blackrock Inc | 2024-06-30 | 415.9 K | |
| Legato Capital Management Llc | 2024-09-30 | 334.3 K | |
| State Street Corp | 2024-06-30 | 288.6 K | |
| Telemark Asset Management, Llc | 2024-09-30 | 8.3 M | |
| Soleus Capital Management, L.p. | 2024-06-30 | 6.1 M |
Biodesix Historical Income Statement
Biodesix Stock Against Markets
Biodesix Corporate Management
| Christopher Vazquez | Controller VP | Profile | |
| James MD | CoChief Officer | Profile | |
| Matt Stauffer | VP Sales | Profile | |
| Dr III | Chief Officer | Profile | |
| Ryan Siurek | Chief Officer | Profile | |
| Heinrich Rder | Founder CTO | Profile |
Additional Tools for Biodesix Stock Analysis
When running Biodesix's price analysis, check to measure Biodesix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodesix is operating at the current time. Most of Biodesix's value examination focuses on studying past and present price action to predict the probability of Biodesix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodesix's price. Additionally, you may evaluate how the addition of Biodesix to your portfolios can decrease your overall portfolio volatility.